Advertisement

Mesothelioma pp 185-203 | Cite as

Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma

  • Federico ReaEmail author
  • Eleonora Faccioli
  • Giuseppe Marulli
Chapter

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive neoplasia with a poor prognosis. The optimal treatment of MPM is still a matter of debate and yet today there is no effective therapy for this tumor. Multimodality treatments, including the association of induction and/or adjuvant therapeutic regimens with surgery, have been reported to give encouraging results.

The aim of surgical approach is to obtain a maximal cytoreduction and/or to control the symptoms, however its curative role/potential is still controversial in the management of this neoplasia. Surgical options include extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D).

Today it is well known that multimodality therapy offers acceptable outcomes, with better results reported for trimodality treatment, even though each therapeutic option has some specific advantages and drawbacks that should be taken into consideration.

Individualization of care for each patient is mandatory in choosing the most appropriate treatment to minimize the complications and to maximize the benefits.

The aim of this chapter is to give an overview on the current state of multimodality treatment in MPM.

Keywords

Mesothelioma Pleurectomy/decortication Extrapleural pneumonectomy Multimodality treatment Radiation therapy Chemotherapy 

References

  1. 1.
    Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesothelioma in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control. 2009;20:935–44.CrossRefGoogle Scholar
  2. 2.
    Zucali PA, De Vincenzo F, Simonelli M, et al. Future developments in the management of malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2009;9:453–67.CrossRefGoogle Scholar
  3. 3.
    Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol. 2006;1:175–6.CrossRefGoogle Scholar
  4. 4.
    Treasure T. What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice. J Thorac Cardiovasc Surg. 2016;151:307–9.CrossRefGoogle Scholar
  5. 5.
    Spaggiari L, Marulli G, Bovolato P, et al. Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. Ann Thorac Surg. 2014;97:1859–65.CrossRefGoogle Scholar
  6. 6.
    Rusch V, Baldini EH, Bueono R, et al. The role of cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the international mesothelioma interest group congress, September 11–14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013;145:909–10.CrossRefGoogle Scholar
  7. 7.
    Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status and cell type determine post-operative long term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63.CrossRefGoogle Scholar
  8. 8.
    Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. J Thorac Oncol. 2012;7:1631–9.CrossRefGoogle Scholar
  9. 9.
    Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgery for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479–95.CrossRefGoogle Scholar
  10. 10.
    Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–46.CrossRefGoogle Scholar
  11. 11.
    Martini N, Bains MS, Beattie EJ Jr. Indications for pleurectomy in malignant effusion. Cancer. 1975;35:734–8.CrossRefGoogle Scholar
  12. 12.
    Cao C, Tian DH, Pataky KA, et al. Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma. Lung Cancer. 2013;81:39–27.CrossRefGoogle Scholar
  13. 13.
    Rice D, Rusch V, Pass H, et al. Recommendation for uniform definitions of surgical techniques for malignant pleural mesothelioma. A consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J Thorac Oncol. 2011;6:1304–12.CrossRefGoogle Scholar
  14. 14.
    Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse pleural mesothelioma of the pleura. Experience with 29 patients. Thorax. 1976;31:15–24.CrossRefGoogle Scholar
  15. 15.
    Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complication after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–46.CrossRefGoogle Scholar
  16. 16.
    Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196–202.CrossRefGoogle Scholar
  17. 17.
    Treasure T, Internullo E, Fiorentino F, et al. A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the society of Thoracic Surgeons (STS). Interact Cardiovasc Thorac Surg. 2011;12:341–6.CrossRefGoogle Scholar
  18. 18.
    Treasure T, Lang-lazdunski L, Waller D, et al. Extrapleural pneumonectomy versus no extrapleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized feasibility study. Lancet Oncol. 2011;12:763–72.CrossRefGoogle Scholar
  19. 19.
    Wanebo HJ, Martini N, Melamed MR, et al. Pleural mesothelioma. Cancer. 1976;38:2481–8.CrossRefGoogle Scholar
  20. 20.
    Lim EM. MARS 2: a feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in patients with malignant pleural mesothelioma (MARS2). http://www.clinicaltrials.gov/show/NCT02040272.
  21. 21.
    Teh E, Fiorentino F, Tan C, et al. A systematic review of lung sparing extirpative surgery for pleural mesothelioma. J R Soc Med. 2011;104:69–80.CrossRefGoogle Scholar
  22. 22.
    Friedberg JS, Culligan MJ, Mick R, et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2012;93:1658–67.CrossRefGoogle Scholar
  23. 23.
    Flores RM. The mesothelioma surgery shift. J Thorac Cardiovasc Surg. 2016;151:485–6.CrossRefGoogle Scholar
  24. 24.
    Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–6.CrossRefGoogle Scholar
  25. 25.
    Lang-Lazdunski L, Bille A, Belcher E, et al. Pleurectomy/decortication, hypertermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2011;6:1746–52.CrossRefGoogle Scholar
  26. 26.
    Bolukbas S, Manegold C, Eberlein M, et al. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer. 2011;71:75–8.CrossRefGoogle Scholar
  27. 27.
    Nakas A, Trousse DS, Martin-Ucar AE, et al. Open lung sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg. 2008;34:886–91.CrossRefGoogle Scholar
  28. 28.
    Flores RM. Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg. 2009;21:149–53.CrossRefGoogle Scholar
  29. 29.
    Sugarbaker DJ, Wolf AS, Chirieac LR, et al. Surgery for malignant pleural mesothelioma. Expert Rev Respir Med. 2010;4:363–72.CrossRefGoogle Scholar
  30. 30.
    Singhal S, Kaiser LR. Malignant pleural mesothelioma: options for management. Surg Clin N Am. 2002;82:797–831.CrossRefGoogle Scholar
  31. 31.
    Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of literature with meta-analysis. Lung Cancer. 2002;38:111–21.CrossRefGoogle Scholar
  32. 32.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.CrossRefGoogle Scholar
  33. 33.
    Zalcman M, Mazieres J, Greiller L, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomized controlled open-label, phase 3 trial. Lancet. 2016;387:1405–14.CrossRefGoogle Scholar
  34. 34.
    Rusch VW. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol. 2002;21:2696–30.Google Scholar
  35. 35.
    Marulli G, Rea F, Nicotra S, et al. Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2010;37:1464–9.CrossRefGoogle Scholar
  36. 36.
    Buduhan G, Menon S, Aye R, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2009;88:870–5.CrossRefGoogle Scholar
  37. 37.
    Weder W, Ketenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451–7.CrossRefGoogle Scholar
  38. 38.
    Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7:737–47.CrossRefGoogle Scholar
  39. 39.
    Okada M, Mimura T, Ohbayashi C, et al. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg. 2008;7:102–6.CrossRefGoogle Scholar
  40. 40.
    Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure. Lung Cancer. 2012;77:151–5.CrossRefGoogle Scholar
  41. 41.
    Trousse DS, Avaro JP, D’Journo XB, et al. Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg. 2009;36:759–63.CrossRefGoogle Scholar
  42. 42.
    Bech C, Sorensen JB. Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report. J Thorac Oncol. 2010;5:735–40.CrossRefGoogle Scholar
  43. 43.
    Hasegawa S, Okada M, Tanaka F, et al. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). Int J Clin Oncol. 2016;21:523–30.CrossRefGoogle Scholar
  44. 44.
    De Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:1413–8.CrossRefGoogle Scholar
  45. 45.
    Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–13.CrossRefGoogle Scholar
  46. 46.
    Pasello G, Marulli G, Polo V, et al. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM). Anticancer Res. 2012;32:5393–400.PubMedGoogle Scholar
  47. 47.
    Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36:1362–9.CrossRefGoogle Scholar
  48. 48.
    Rea F, Favaretto A, Marulli G, et al. Phase II trial of neaodjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer. 2013;13:22.CrossRefGoogle Scholar
  49. 49.
    Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006;1:289–95.CrossRefGoogle Scholar
  50. 50.
    Bille A, Belcher E, Raubenheimer H, et al. Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospital. Gen Thorac Cardiovasc Surg. 2012;60:289–96.CrossRefGoogle Scholar
  51. 51.
    Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer. 2007;57:89–95.CrossRefGoogle Scholar
  52. 52.
    Bece A, Tin MM, Martin D, et al. Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: toxicity and outcomes at an Australian institution. J Med Imaging Radiat Oncol. 2015;59:355–62.CrossRefGoogle Scholar
  53. 53.
    Chance WW, Rice DC, Allen PK, et al. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015;91:149–56.CrossRefGoogle Scholar
  54. 54.
    Thieke C, Nicolay NH, Sterzing F, et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity modulated radiotherapy. Radiat Oncol. 2015;10:267.CrossRefGoogle Scholar
  55. 55.
    Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–95.CrossRefGoogle Scholar
  56. 56.
    Gupta V, Mychalczak B, Krug LM, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045–52.CrossRefGoogle Scholar
  57. 57.
    Lee TT, Everett DL, Shu HG, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002;124:1183–9.CrossRefGoogle Scholar
  58. 58.
    Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65(3):640–5.CrossRefGoogle Scholar
  59. 59.
    Rimner A, Zauderer MJ, Gomez DR, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol. 2010;5:735–40.Google Scholar
  60. 60.
    Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8:238–45.CrossRefGoogle Scholar
  61. 61.
    Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84:1685–93.CrossRefGoogle Scholar
  62. 62.
    Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319–26.CrossRefGoogle Scholar
  63. 63.
    Gupta V, Krug LM, Laser B, et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol. 2009;4:746–50.CrossRefGoogle Scholar
  64. 64.
    Cho BC, Feld R, Leighl N, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the “SMART” approach for resectable malignant pleural mesothelioma. J Thorac Oncol. 2014;9:397–402.CrossRefGoogle Scholar
  65. 65.
    Minatel E, Trovo M, Bearz A, et al. Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure and prognostic factor. Int J Radiat Oncol Biol Phys. 2015;93:606–13.CrossRefGoogle Scholar
  66. 66.
    Baldini EH, Richards WG, Gill RR, et al. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2015;149:1374–81.CrossRefGoogle Scholar
  67. 67.
    Lang-Lazdunski L, Bille A, Papa S, et al. Pleurectomy/decortication, hypertermic pleural lavage with povidone-iodine, prophylactic radiotherapy and systemic chemotherapy in patient with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2015;149:558–65.CrossRefGoogle Scholar
  68. 68.
    Sugarbaker PH, Stuart OA, Eger C. Pharmacokinetics of hypertermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroenterol Res Pract. 2012;2012:471205.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Bedirhan MA, Cansever L, Demir A, et al. Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extendend pleurectomy? J Thorac Dis. 2013;5:446–54.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Friedberg JS, Simone CB, Culligan MJ 2nd, et al. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann Thorac Surg. 2017;103:912–9.CrossRefGoogle Scholar
  71. 71.
    Nakas A, von Meyenfeldt E, Lau K, et al. Long-term results after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group stage T3-T4) non-sarcomatoid malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2012;41:1031–6.CrossRefGoogle Scholar
  72. 72.
    Patel PR, Yoo S, Broadwater G, et al. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83:362–8.CrossRefGoogle Scholar
  73. 73.
    Tonoli S, Vitali P, Scotti V, et al. Adjuvant radiotherapy after extra-pleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series. Radiother Oncol. 2011;101:311–5.CrossRefGoogle Scholar
  74. 74.
    Luckraz H, Rahman M, Patel N, et al. Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg. 2010;37:552–6.CrossRefGoogle Scholar
  75. 75.
    Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hypertermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138:405–11.CrossRefGoogle Scholar
  76. 76.
    Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg. 2009;138:619–24.CrossRefGoogle Scholar
  77. 77.
    Miles EF, Larrier NA, Kelsey CR, et al. Intensity modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys. 2008;71:1143–50.CrossRefGoogle Scholar
  78. 78.
    Van Sandick JW, Kappers I, Baas P, et al. Surgical treatment in the management of malignant pleural mesothelioma: a single institution’s experience. Ann Surg Oncol. 2008;15:1757–64.CrossRefGoogle Scholar
  79. 79.
    Allen AM, Den R, Wong JS, et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys. 2007;68:1366–74.CrossRefGoogle Scholar
  80. 80.
    Lucchi M, Chella A, Melfi F, et al. A phase II study of intrapleural immune-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2007;31:529–35.CrossRefGoogle Scholar
  81. 81.
    Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res. 1996;81:193–211.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Federico Rea
    • 1
    Email author
  • Eleonora Faccioli
    • 1
  • Giuseppe Marulli
    • 1
  1. 1.Thoracic Surgery Unit, Department of Cardiologic, Thoracic and Vascular SciencesUniversity of PadovaPadovaItaly

Personalised recommendations